Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Thyrotropin Receptor Antibody Levels at Diagnosis and After Thionamide Course Predict Graves’ Disease Relapse
source: Thyroid : Official Journal of the American Thyroid Association
year: 2016
authors: Tun NN, Beckett G, Zammitt NN, Strachan MW, Seckl JR, Gibb FW
summary/abstract:Background:
Thionamides are associated with a high risk of recurrence following cessation. Thyrotropin receptor-stimulating antibody (TRAb) levels at diagnosis and/or after thionamides may be biomarkers of this risk. This study assesses the natural history of Graves’ thyrotoxicosis following thionamide withdrawal and factors that predict recurrence, particularly TRAb levels at diagnosis and cessation.
Methods:
An observational study was conducted of patients with a first presentation of Graves’ disease, who were prescribed (and completed) a course of primary thionamide treatment (n = 266) in a university teaching hospital endocrine clinic. Recurrence rates over four years and factors predictive of recurrent thyrotoxicosis were assessed.
Results:
The relapse rate was 31% at one year and 70% at four years. Younger age (39 years [range 30-49 years] vs. 47 years [range 37-53 years]; p = 0.011), higher TRAb levels at diagnosis (8.8 IU/L [range 5.3-17.0 IU/L] vs. 5.7 IU/L [range 4.1-9.1 IU/L]; p = 0.003), and higher TRAb levels at cessation of therapy (1.2 IU/L [range 0-2.3 IU/L] vs. <0.9 IU/L [range 0-1.3 IU/L]; p = 0.003) were associated with a higher risk of relapse. By four years, cessation TRAb <0.9 IU/L was associated with a 58% risk of recurrence compared with 82% with TRAb >1.5 IU/L (p = 0.001). TRAb at diagnosis >12 IU/L was associated with an 84% risk of recurrence over four years compared with 57% with TRAbs <5 IU/L (p = 0.002).
Conclusion:
High TRAb at diagnosis and/or positive TRAb at cessation of therapy suggest a high likelihood of relapse, mostly within the first two years. They stratify patients likely to need definitive therapy (radioiodine or surgery).
DOI: 10.1089/thy.2016.0017
read more
myBinderRelated Content
-
Antithyroid Drugs (Beyond the Basics)Antithyroid drugs have several benefits ...
-
Predicting Risk of Recurrent Thyrotoxicosis Following Thionamide Withdrawal in Graves’ DiseaseBackground/Aim: Thionamides are a safe ...
-
Relation Between Therapy for Hyperthyroidism and the Course of Graves’ OphthalmopathyBackground: The chief clinical characte...
-
Graves’ Disease and Pregnancy PlanningBoth hypothyroidism and hyperthyroidism ...
-
Effect of Long-Term Continuous Methimazole Treatment of Hyperthyroidism: Comparison With RadioiodineObjective: To investigate the long-term...
-
Comparative Effectiveness of Treatment Choices for Graves’ Hyperthyroidism: A Historical Cohort StudyBackground: The optimum therapy for Gra...
-
Thyroglobulin Autoantibodies are Associated With Refractoriness to Antithyroid Drug Treatment for Graves’ Dise...Objective: The recurrence rate associat...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Facebook
Google